Introduction
In sepsis, none of the prognostic biomarkers employed have shown the necessary sensitivity and specificity to be used routinely in clinical practice. In this research we analyze the relationship between proADM an other routinely biomarkers employed in the management of severe sepsis with mortality.
Methods
Prospective observational study. Plasmatic levels of ProADM, C reactive protein (CRP) and procalcitonin (PCT) Multivariate 
Conclusions
ProADM is a consistent marker of mortality risk and severity along time in severe sepsis and septic shock. This provides a selective advantage over other biomarkers as prognostic tool. The inclusion in clinical practice could help to intensivist, along with the rest of biomarkers and scores of severity, for better optimization in making decisions for management and establish prognosis of this disease.
